Track topics on Twitter Track topics that are important to you
CASI Pharma announced China approval to start clinical trials of CNCT19, a CD19 CAR-T treatment, in leukemia and lymphoma patients. Earlier this year, CASI acquired global rights to the candidate from Juventas Cell Therapy of Beijing in exchange for an $11.6 million investment in Juventas rather than an upfront payment. Juventas retains responsibility for trials of CNCT19. CASI, a Maryland-China biopharma, said the CD19 CAR-T therapy will be tested in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and relapsed/refractory B-cell non-Hodgkin lymphoma. More details....
Stock Symbol: (NSDQ: CASI)
Share this with colleagues:
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...